Full-Time

Director – Precision Medicine

Clinical Diagnostics

Posted on 11/1/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$202k - $336.6k/yr

+ Annual Bonus Potential + Equity Awards

Westchester County, NY, USA + 1 more

More locations: Middlesex, NJ, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Requirements
  • Minimum of 10+ years of experience in biotech/pharmaceutical industry and/or diagnostic industry with strong knowledge of GCP, CAP/CLIA, US FDA and IVDR laboratory and diagnostic requirements
  • Bachelor’s degree in sciences required, advanced degree or PhD preferred
  • Demonstrated experience in clinical trial and diagnostic development planning and project management
  • Experience with project management tools to provide timelines and identify milestones
  • Strong organization, collaboration, communication and presentation skills
  • Excellent at thinking and working on the fly and under pressure, problem solving and providing consultative approaches
  • Experience working with cross-functional clinical study teams
  • Understanding of GxP, CAP/CLIA, FDA, PMDA, IVDR and applicable ISO regulations
  • Strong understanding of laboratory practices, validation procedures and regulatory requirements
Responsibilities
  • manage and deliver the execution of diagnostic projects (CDx, IVD, etc.) to support Regeneron’s drug development pipeline in partnership with clinical, precision medicine, research and regulatory colleagues.
  • This is a leadership role within Regeneron’s clinical diagnostics team to provide portfolio management, program/project management, strategic input and execution of complex diagnostic strategies to support clinical programs across multiple therapeutic areas.
  • lead and partner cross-functionally within the Clinical Diagnostics team, Precision Medicine Strategy, Laboratory Operations, to directly lead and/or lead resources with and without authority.
  • influence and lead the build of a framework to ensure effective planning and handoff from diagnostic strategy to execution phase with both internal and external resources serving as a key point of contact with internal clinical teams, external diagnostic partners, laboratories and vendors.
  • The candidate must have strong expertise in drug development planning and CDx/IVD development with pharmaceutical companies.
  • Proactively plan, manage and execute assigned portfolio of diagnostic projects supporting Regeneron’s drug development programs
  • Continuously review Regeneron’s drug development pipeline and portfolio, build relationships with key stakeholders in clinical development units and other functions, and facilitate diagnostic assessments to ensure the Dx team is supporting all relevant clinical programs
  • Leverage tools and other resources to maintain portfolio and project level information to track timelines/deliverables and communicate effectively to cross-functional stakeholders
  • Develop, build and implement processes and tools to support and the Diagnostics function to ensure quality, efficient and timely delivery
  • Effectively partner with external diagnostic manufacturers, laboratories and vendors to support delivery of diagnostic tools and strategies. Provide oversight and leadership of external relationships as needed
  • Represent Clinical Diagnostics team as an expert and leader to drive knowledge of diagnostic delivery, learning, regulatory impacts and operational considerations
  • Deliver executive level presentations on Regeneron’s diagnostic strategies
  • Define the diagnostic delivery plan and serve as the main point of contact internally and externally for the duration of the diagnostic project
  • Identify, communicate and manage risks to the strategy and delivery plan
  • Develop, align and oversee execution of diagnostic development, operational and commercial plans
  • Manage (with and without authority) a team of resources contributing to delivery of the diagnostic strategy
  • Communicate effectively with stakeholders to resolve quality issues and ensure continuous improvement internally and with our Dx partners and labs
  • Develop and maintain project plans to closely track CDx development and CDx regulatory activities against clinical drug development and study timelines
  • Review clinical protocols, informed consent documents and other clinical trial deliverables and work with other key reviewers to ensure accuracy of diagnostic language
  • Demonstrate high acumen regarding drug development, assay development and laboratory build, quality and execution for use of IVDs and CDx in clinical trials
  • Oversee requirements for laboratory specifications, builds and start up activities to ensure diagnostic assay is ready for clinical trial patient testing
  • Lead oversight of critical samples, testing processes and quality; work with teams to resolve any related issues and escalate as needed
  • Serve as an active member of clinical study teams to ensure Dx/CDx planning is in line with clinical study plans and to ensure study teams are informed of Dx/CDx activities, status, budget and timelines
  • Support Dx/CDx Strategy Lead and Dx/CDx management with information relevant to driving program strategy in participation with Strategic Program Teams
  • Stakeholder Management & External Collaborations
  • Manage and integrate with team members from functional groups across Regeneron using data driven approaches
  • Partner with laboratory operations team to align on biomarker testing and sample oversight activities
  • Work closely with external diagnostic partners, central laboratories and specialty testing labs
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent global sales surged 33% to $4.9B in Q1 2026, treating 1.4M patients across nine indications.
  • Libtayo net sales grew 54% to $438M in Q1 2026 from CSCC and lung cancer uptake.
  • $27B US R&D and manufacturing commitment secures three-year tariff relief via April 2026 Trump deal.

What critics are saying

  • Biosimilar aflibercept from Viatris erodes legacy EYLEA sales, dropping combined franchise 10% to $941M in Q1 2026.
  • Sanofi renegotiates Dupixent profit-sharing as sales hit $4.9B, cutting Regeneron's 25-50% economics by 2028.
  • Trump most-favored-nation deal mandates Medicaid price cuts on EYLEA and Dupixent, slashing margins 30-50% by mid-2027.

What makes Regeneron Pharmaceuticals unique

  • Proprietary VelociSuite technologies enable rapid homegrown drug discovery across modalities.
  • Developed EYLEA HD with unique 5-month dosing for wet AMD approved by FDA in Q1 2026.
  • Pioneered Otarmeni, first in vivo gene therapy for OTOF-related hearing loss, FDA-approved April 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Endpoints News
Apr 13th, 2026
Regeneron wades into radiopharma through $40M upfront deal with telix.

Regeneron wades into radiopharma through $40M upfront deal with telix. News reporter. Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Think Endpoints Company is worth reading - tell google. Confirm Endpoints as a trusted biopharma news source ENDPOINTS CAREERS TCG stealth clinic-ready newco.

AllSci
Apr 13th, 2026
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal.

Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal. April 13, 2026 Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly develop and commercialize next-generation antibody-based radiopharmaceutical therapies across multiple solid tumor indications. The agreement pairs Telix's radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron's antibody discovery technologies, including its VelocImmune and VelociSuite platforms, to generate a pipeline of radiolabeled biologics. Specific tumor targets have not been disclosed. Deal specifics. Under the deal terms, Telix will receive an upfront payment of USD 40 million from Regeneron for access to its radiopharmaceutical manufacturing platform across four initial therapeutic programs. Should Telix elect to opt out of co-funding on any individual program, it becomes eligible to receive up to USD 535 million in development and commercial milestone payments per program, plus low double-digit royalties on net sales, with an aggregate milestone ceiling of USD 2.1 billion across all programs. Where Telix remains in the co-funding model, the two companies will share equally in global development costs and commercialization profits on a 50/50 basis, with Telix retaining the option to co-promote certain products. The collaboration covers four initial therapeutic programs, with Regeneron holding the option to expand to four additional programs subject to further upfront payments. The parties will also jointly develop radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a defined percentage of profits. The exact percentage was not disclosed. The structure gives Telix a per-program election right at a defined decision point: co-fund and share in global profits equally, or opt out and revert to a milestone-plus-royalty economics model. This optionality allows Telix to allocate capital selectively depending on program progression and resource constraints, while preserving upside participation across the portfolio. The agreement is global in scope, with no geographic carve-outs or territorial allocations disclosed. No equity investment by either party in the other was announced in connection with the transaction. The drug programs will combine Regeneron's antibody targeting components, drawn from its portfolio of antibodies generated through VelocImmune mice, with Telix's radiolabeling and manufacturing capabilities. The modality class is antibody-based radiopharmaceutical therapy, in which a tumor-antigen-binding antibody serves as the targeting vehicle for a therapeutic radionuclide payload. The collaboration also encompasses potential bispecific antibody formats, given Regeneron's established expertise in that area. Regeneron noted in its public commentary that it intends to explore these agents as monotherapy and in rational combination with its immunotherapy platform, citing lung cancer as one area of interest where its PD-1 inhibitor is already in use. The specific antigens, antibody names, and radionuclide payloads for the collaboration programs have not been publicly identified. The theranostic component of the agreement, pairing matched diagnostic and therapeutic agents using the same antibody targeting vector, supports patient stratification and dosimetry assessment ahead of and during treatment. Telix will lead commercialization of the diagnostic assets developed under the collaboration. Strategic implications. Regeneron's entry into radiopharmaceutical oncology drug development marks a modality expansion for a company whose oncology portfolio has been anchored in antibody-based immunotherapy. The company indicated it views targeted radiopharmaceuticals as a frontier in oncology and has framed the collaboration as an opportunity to apply its antibody discovery engine to a delivery modality it has not previously pursued commercially. For Telix, the arrangement provides validation of its radiopharmaceutical manufacturing infrastructure as a platform asset capable of attracting large-scale co-development partnerships. Telix's existing commercial radiopharmaceutical portfolio includes Illuccix kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC injection (also known as 68Ga-PSMA-11 injection), approved by the US FDA as a prostate cancer imaging agent. In addition, the firm announced on April 9, 2026, that the US FDA has accepted an NDA filing for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer). Your email address will not be published. Required fields are marked *

GlobalData
Apr 13th, 2026
Telix and Regeneron to co-develop radiopharmaceutical therapies.

Telix and Regeneron to co-develop radiopharmaceutical therapies. The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global manufacturing and supply chain infrastructure with Regeneron's biologics knowledge, particularly in bispecific antibody discovery. Regeneron will initially provide Telix with an upfront cash payment of $40m for access to the latter's radiopharmaceutical manufacturing platform for four therapeutic initiatives. There is an option for Regeneron to expand to another four programmes, which would involve further upfront payments. Both companies will equally share the costs and potential profits worldwide, with Telix optionally co-promoting certain products. If Telix chooses to step back from funding a specific programme, it could gain up to $535m in developmental and commercial milestones, in addition to low double-digit royalties on subsequent net sales. Regeneron oncology and antibody technology research senior vice-president John Lin said: "At Regeneron, Pharmaceutical Technology follow the science to determine the best therapeutic approach for each disease, continuously expanding its toolbox of treatment modalities - from monoclonal and bispecific antibodies to cell therapies and beyond. "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need." The collaboration will include several solid tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology. It reflects a joint focus on precision oncology, seeking to enhance patient selection and assess treatment responses through new radio-diagnostics. The companies also plan to develop diagnostic assets, where Telix will spearhead the commercialisation efforts, and Regeneron will receive a predetermined share of the profits. In December 2025, Regeneron teamed up with Tessera Therapeutics to develop and commercialise Tessera's rare disease in vivo gene writing programme, TSRA-196. Give your business an edge with its leading industry insights.

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

INACTIVE